Cargando…

Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial

BACKGROUND: Progress in vitrification techniques has allowed reproductive physicians to consider new strategies for using progestin as an alternative to a GnRH analogue to improve in vitro fertilisation (IVF). However, the role of progestin in blocking luteinising hormone (LH) surges and its potenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yun, Kuang, Yanping, Chen, Qiuju, Cai, Renfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106816/ https://www.ncbi.nlm.nih.gov/pubmed/30134964 http://dx.doi.org/10.1186/s13063-018-2850-x

Ejemplares similares

Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial
por: Chen, Qiuju, et al.
Publicado: (2019)

Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats
por: He, Wen, et al.
Publicado: (2017)

Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization
por: Kochhar, Puneet Kaur, et al.
Publicado: (2020)

Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles
por: Tandulwadkar, Sunita, et al.
Publicado: (2023)

A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
por: Ezcurra, Diego, et al.
Publicado: (2014)

Luteinising hormone-based protocol versus traditional flexible gonadotropin-releasing hormone antagonist protocol in women with normal ovarian response: study protocol for a non-inferiority trial
por: Lv, Ya-su, et al.
Publicado: (2021)

Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders
por: Chen, Qiuju, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders
por: Eser, Ahmet, et al.
Publicado: (2018)

The effect of human chorionic gonadotrophin contained in human menopausal gonadotropin on the clinical outcomes during progestin-primed ovarian stimulation
por: Zhu, Xiuxian, et al.
Publicado: (2017)

Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF
por: Huang, Jialyu, et al.
Publicado: (2019)

Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles
por: Sun, Lihua, et al.
Publicado: (2018)

Recurrent Endometrial Stromal Sarcoma: Treatment with a Progestin and Gonadotropin Releasing Hormone Agonist
por: duPont, Nefertiti Chianti, et al.
Publicado: (2010)

Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization
por: Lee, Hwajeong, et al.
Publicado: (2018)

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
por: Plowman, P. N., et al.
Publicado: (1986)

Ganirelix and the prevention of premature luteinizing hormone surges
por: Mannaerts, Bernadette
Publicado: (2023)

Original delayed-start ovarian stimulation protocol with a gonadotropin-releasing hormone antagonist, medroxyprogesterone acetate, and high-dose gonadotropin for poor responders and patients with poor-quality embryos
por: Takeuchi, Kazuhiro, et al.
Publicado: (2023)

Measuring luteinising hormone pulsatility with a robotic aptamer-enabled electrochemical reader
por: Liang, Shaolin, et al.
Publicado: (2019)

Neonatal outcomes and congenital malformations in children born after progestin-primed ovarian stimulation protocol
por: Li, Danjun, et al.
Publicado: (2022)

Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations
por: Zhou, Ruiqiong, et al.
Publicado: (2023)

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989)

Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial
por: Ashrafi, Mahnaz, et al.
Publicado: (2018)

Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders
por: Liu, Yuan, et al.
Publicado: (2021)

Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.
por: Bokser, L., et al.
Publicado: (1990)

Effect of Switching from a Progestin-Primed Ovarian Stimulation Protocol to a Modified Ultra-Long Protocol Among Women Who Had 1 Progestin-Primed Ovarian Stimulation (PPOS) Failure Verses Those Who Had 2 PPOS Failures
por: Shen, Xi, et al.
Publicado: (2020)

Microdose Flare-up Gonadotropin-releasing Hormone (GnRH) Agonist Versus GnRH Antagonist Protocols in Poor Ovarian Responders Undergoing Intracytoplasmic Sperm Injection
por: Boza, Aysen, et al.
Publicado: (2016)

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
por: Yates, C, et al.
Publicado: (2005)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
por: Secreto, G., et al.
Publicado: (1983)

Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles
por: Albeitawi, Soha, et al.
Publicado: (2022)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Luteinizing Hormone Suppression by Progestin-Primed Ovarian Stimulation Is Associated With Higher Implantation Rate for Patients With Polycystic Ovary Syndrome Who Underwent in vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: Comparing With Short Protocol
por: Chen, Chen, et al.
Publicado: (2022)

Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study
por: Aflatoonian, Abbas, et al.
Publicado: (2018)

Chitosan-Nanoconjugated Hormone Nanoparticles for Sustained Surge of Gonadotropins and Enhanced Reproductive Output in Female Fish
por: Rather, Mohd Ashraf, et al.
Publicado: (2013)

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
por: Rzewuska, Anna Maria, et al.
Publicado: (2023)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
por: Jain, Shikha, et al.
Publicado: (2016)

Effects of letrozole co-treatment on the cumulative live-birth rate among normal responders in gonadotropin-releasing hormone antagonist cycles
por: Zhang, Shuyi, et al.
Publicado: (2022)

A Higher Estradiol Rise After Dual Trigger in Progestin-Primed Ovarian Stimulation Is Associated With a Lower Oocyte and Mature Oocyte Yield in Normal Responders
por: Huang, Jialyu, et al.
Publicado: (2019)

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
por: Langley, Ruth E., et al.
Publicado: (2016)

Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF
por: Nakao, Kazuki, et al.
Publicado: (2021)

Prevention of Premature Ovulation by Administration of Gonadotropin Releasing Hormone Antagonist the day After Ovulation Triggering in Diminished Ovarian Reserve Patients
por: Sik, Bulat Aytek, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rlcocubep48ltf38s2hi8c89rt